Pulmonx Statistics
Total Valuation
Pulmonx has a market cap or net worth of $97.06 million. The enterprise value is $97.43 million.
| Market Cap | 97.06M |
| Enterprise Value | 97.43M |
Important Dates
The last earnings date was Wednesday, July 29, 2026, after market close.
| Earnings Date | Jul 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Pulmonx has 42.95 million shares outstanding. The number of shares has increased by 4.69% in one year.
| Current Share Class | 42.95M |
| Shares Outstanding | 42.95M |
| Shares Change (YoY) | +4.69% |
| Shares Change (QoQ) | +1.36% |
| Owned by Insiders (%) | 5.73% |
| Owned by Institutions (%) | 54.63% |
| Float | 37.70M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.11 |
| Forward PS | 1.02 |
| PB Ratio | 2.48 |
| P/TBV Ratio | 2.68 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.11 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.32, with a Debt / Equity ratio of 1.43.
| Current Ratio | 4.32 |
| Quick Ratio | 3.36 |
| Debt / Equity | 1.43 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.29 |
Financial Efficiency
Return on equity (ROE) is -88.87% and return on invested capital (ROIC) is -26.15%.
| Return on Equity (ROE) | -88.87% |
| Return on Assets (ROA) | -22.10% |
| Return on Invested Capital (ROIC) | -26.15% |
| Return on Capital Employed (ROCE) | -49.09% |
| Weighted Average Cost of Capital (WACC) | 5.61% |
| Revenue Per Employee | $295,412 |
| Profits Per Employee | -$162,554 |
| Employee Count | 296 |
| Asset Turnover | 0.67 |
| Inventory Turnover | 1.23 |
Taxes
In the past 12 months, Pulmonx has paid $596,000 in taxes.
| Income Tax | 596,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +44.87% in the last 52 weeks. The beta is 0.28, so Pulmonx's price volatility has been lower than the market average.
| Beta (5Y) | 0.28 |
| 52-Week Price Change | +44.87% |
| 50-Day Moving Average | 1.57 |
| 200-Day Moving Average | 1.64 |
| Relative Strength Index (RSI) | 64.87 |
| Average Volume (20 Days) | 878,796 |
Short Selling Information
The latest short interest is 1.06 million, so 2.47% of the outstanding shares have been sold short.
| Short Interest | 1.06M |
| Short Previous Month | 1.06M |
| Short % of Shares Out | 2.47% |
| Short % of Float | 2.81% |
| Short Ratio (days to cover) | 2.12 |
Income Statement
In the last 12 months, Pulmonx had revenue of $87.44 million and -$48.12 million in losses. Loss per share was -$1.15.
| Revenue | 87.44M |
| Gross Profit | 67.38M |
| Operating Income | -46.31M |
| Pretax Income | -47.52M |
| Net Income | -48.12M |
| EBITDA | -45.49M |
| EBIT | -46.31M |
| Loss Per Share | -$1.15 |
Balance Sheet
The company has $55.84 million in cash and $56.21 million in debt, with a net cash position of -$368,000 or -$0.01 per share.
| Cash & Cash Equivalents | 55.84M |
| Total Debt | 56.21M |
| Net Cash | -368,000 |
| Net Cash Per Share | -$0.01 |
| Equity (Book Value) | 39.20M |
| Book Value Per Share | 0.91 |
| Working Capital | 67.73M |
Cash Flow
In the last 12 months, operating cash flow was -$30.56 million and capital expenditures -$112,000, giving a free cash flow of -$30.67 million.
| Operating Cash Flow | -30.56M |
| Capital Expenditures | -112,000 |
| Depreciation & Amortization | 819,000 |
| Net Borrowing | 1.68M |
| Free Cash Flow | -30.67M |
| FCF Per Share | -$0.71 |
Margins
Gross margin is 77.06%, with operating and profit margins of -52.96% and -55.03%.
| Gross Margin | 77.06% |
| Operating Margin | -52.96% |
| Pretax Margin | -54.34% |
| Profit Margin | -55.03% |
| EBITDA Margin | -52.02% |
| EBIT Margin | -52.96% |
| FCF Margin | n/a |
Dividends & Yields
Pulmonx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.69% |
| Shareholder Yield | -4.69% |
| Earnings Yield | -49.57% |
| FCF Yield | -31.60% |
Analyst Forecast
The average price target for Pulmonx is $3.40, which is 50.44% higher than the current price. The consensus rating is "Buy".
| Price Target | $3.40 |
| Price Target Difference | 50.44% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 6.40% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pulmonx has an Altman Z-Score of -5.94 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.94 |
| Piotroski F-Score | 3 |